ReviewSeminars in nuclear medicine2014
Cardiac PET perfusion tracers: current status and future directions.
Review in Seminars in nuclear medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Correlation Between Epicardial Adipose Tissue and PET Cardiac Perfusion: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Assessment of Myocardial Viability in Ischemic Cardiomyopathy With Reduced Left Ventricular Function Undergoing Coronary Artery Bypass Grafting.Clinical cardiology · 2024Pooled it
- Subendocardial quantification enhances coronary artery disease detection inEuropean journal of nuclear medicine and molecular imaging · 2025Trial
- 18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease categorization.European heart journal. Cardiovascular Imaging · 2022Trial
- Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of theJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Pharmacologic Stress Myocardial Perfusion Imaging with SPECT and PET in Liver Transplant Candidates: Physiologic Limitations, Current Evidence, and Future Directions.Current cardiology reports · 2026Review
- Vascular changes in hypertrophic cardiomyopathy.Cardiovascular research · 2026Review
- Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments: A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC.European heart journal. Cardiovascular Imaging · 2026Review
- Impact of software tools and kinetic model selection on myocardial blood flow and flow reserve quantitation inJournal of applied clinical medical physics · 2026Article
- Sarcolemmal and mitochondrial membrane potentials measured ex vivo and in vivo in the heart by pharmacokinetic modelling of [The Journal of physiology · 2026Article
- Multicenter Evaluation of Myocardial Flow Reserve as a Prognostic Marker for Mortality inCirculation. Cardiovascular imaging · 2026Article
- Review
- Patient-centric performance and interpretation of positron emission tomography /computed tomography myocardial perfusion imaging: a clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology.European heart journal. Imaging methods and practice · 2026Review
- Simultaneous measurement of coronary sinus flow and myocardial flow reserve using hybridThe international journal of cardiovascular imaging · 2025Article
- Flurpiridaz F18: a new era in nuclear cardiac imaging - the first FDA-approved radiotracer in 30 years.Annals of medicine and surgery (2012) · 2025Article
- PET MPI With F-18 FlurpiridazVersus Rb-82: Insights Into Blood Flow and Splenic Switch-Off.JACC. Case reports · 2025Article
- Development of myocardial perfusion imaging from coronary angiography for clinical application.Radiological physics and technology · 2025Article
- Synthesis and preliminary evaluation of cardiac imaging with [RSC pharmaceutics · 2025Article
- A comparison of magnetocardiography with noninvasive cardiac testing in the evaluation of patients with chest pain.American heart journal plus : cardiology research and practice · 2025Article
- Biodistribution, Safety Profile, and Radiation Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
PET myocardial perfusion imaging (MPI) is increasingly being used for noninvasive detection and evaluation of coronary artery disease. However, the widespread use of PET MPI has been limited by the shortcomings of the current PET perfusion tracers. The availability of these tracers is limited by the need for an onsite ((15)O water and (13)N ammonia) or nearby ((13)N ammonia) cyclotron or commitment to costly generators ((82)Rb). Owing to the short half-lives, such as 76 seconds for (82)Rb, 2.06 minutes for (15)O water, and 9.96 minutes for (13)N ammonia, their use in conjunction with treadmill exercise stress testing is either not possible ((82)Rb and (15)O water) or not practical ((13)N ammonia). Furthermore, the long positron range of (82)Rb makes image resolution suboptimal and its low myocardial extraction limits its defect resolution. In recent years, development of an (18)F-labeled PET perfusion tracer has gathered considerable interest. The longer half-life of (18)F (109 minutes) would make the tracer available as a unit dose from regional cyclotrons and allow use in conjunction with treadmill exercise testing. Furthermore, the short positron range of (18)F would result in better image resolution. Flurpiridaz F 18 is by far the most thoroughly studied in animal models and is the only (18)F-based PET MPI radiotracer currently undergoing clinical evaluation. Preclinical and clinical experience with Flurpiridaz F 18 demonstrated a high myocardial extraction fraction, high image and defect resolution, high myocardial uptake, slow myocardial clearance, and high myocardial-to-background contrast that was stable over time-important properties of an ideal PET MPI radiotracer. Preclinical data from other (18)F-labeled myocardial perfusion tracers are encouraging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.